What You Should Know
– Avalon Healthcare Solutions, the leader in diagnostic intelligence, has announced a strategic investment from Francisco Partners and WindRose Health Investors.
– The capital will be used to accelerate the expansion of Avalon’s proprietary Diagnostic Insights Platform, which currently supports more than 30 health plans and over 90 million members nationwide. The platform focuses on automating diagnostic policy and utilizing advanced analytics to transform clinical outcomes across the entire test-to-treatment journey.
Scaling the “Test-to-Treatment” Journey
While many health techs talk about AI in the abstract, Avalon’s play is very concrete. They’ve built a proprietary Diagnostic Insights Platform and a patented automation engine (APEA) that enforces clinical policies in real time.
With this new capital, Avalon is targeting a few specific growth areas:
- Self-Funded Market Expansion: Starting in 2026, they are moving beyond traditional health plans to serve TPAs and Brokers.
- Policy Automation: They are speeding up the move toward “evidence-based” automation, which is critical as administrative waste continues to eat up nearly a quarter of every healthcare dollar.
- Predictive Analytics: Using diagnostic data to see around corners and improve outcomes before a patient even starts treatment.
Why This Matters
Avalon is currently sitting on a massive footprint, managing 90 million members and processing 18 million claims every month. This isn’t just another funding round; it’s a signal that “diagnostic intelligence” is becoming the new bedrock for any health plan trying to actually make value-based care work in 2026.
Avalon isn’t changing its team or its pricing, but they are clearly changing the scale of the game. As Bill Kerr, MD, CEO of Avalon, put it, they are now accelerating the innovation that lets them own the “test-to-treatment” journey. In a year defined by agility over budget size, Avalon is proving that the smartest way to manage a patient’s health is to start with the data that drives 70% of their doctor’s decisions.
